 Ampio Pharmaceuticals, Inc. NYSE American: AMPE, a pre-revenue development stage biopharmaceutical company focused on the development of immunology based therapies to treat prevalent inflammatory conditions announced today that it was featured on a FOX segment titled, Englewood pharmaceutical company looking to treat COVID-19 patients with anti-inflammatory drug, reported by an affiliated television station in Denver, Colorado. The primary cause of death associated with SARS-Cov-2 COVID-19 infection is Acute Respiratory Distress Syndrome ARDS, and there are no approved treatments for ARDS or COVID-19. The segment featured the Companys application to the FDA to study the treatment of COVID-19 induced ARDS with nebulized Ampion. 